SWOG clinical trial number
SWOG-8719

Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients without Prior Endocrine Manipulation

Closed
Phase
Accrual
87%
Published
Abbreviated Title
Evaluations of Didemnin B or Ifosfamide/Mesna in Endocrine Resistant Prostate Cancer and of Ifosfamide/Mesna in Patients without Prior Endocrine Manipulation
Activated
11/01/1988
Closed
05/15/1993

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1996

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.

SK Williamson;MK Wolf;MA Eisenberger;MA O'Rourke;W Brannan;ED Crawford American Journal of Clinical Oncology (CCT) 19(4):368-370

1995

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.

SK Williamson;MK Wolf;MA Eisenberger;M O'Rourke;W Brannon;ED Crawford Investigational New Drugs 13:167-170

1994

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.

M Hussain;M Wolf;E Marshall;ED Crawford;M Eisenberger Journal of Clinical Oncology 12(9):1868-1875

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase